Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Univ Leuven K U Leuven R D, Ucb Biopharma SprlfiledCriticalKatholieke Univ Leuven K U Leuven R D
Publication of ECSP15031293ApublicationCriticalpatent/ECSP15031293A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
Una serie de derivados de pirazolo[3,4-d]pirimidina que se sustituyen en la posición 4 mediante un resto monocíclico diaza, bicíclico con puente o espirocíclico, son beneficiosos en el tratamiento y/o prevención de varias dolencias humanas, incluidos trastornos inflamatorios, autoinmunes y oncológicos; enfermedades virales y malaria; y rechazo de trasplante de órganos y células.A series of pyrazolo [3,4-d] pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic, or spirocyclic moiety, are beneficial in the treatment and / or prevention of various human ailments, including inflammatory disorders. , autoimmune and oncological; viral diseases and malaria; and organ and cell transplant rejection.
ECIEPI201531293A2012-12-202015-07-20
THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES
ECSP15031293A
(en)
PHARMACEUTICAL FORMULATIONS, PROCESS, SOLID FORMS AND METHODS OF USE RELATED TO 1-ETIL-7- (2-METHYL-6- (1H-1,2,4-TRIAZOL-3-II) PI RIDIN-3-II) -3 , 4-HYDROPIRAZINE [2,3-B] PIRAZIN-2 (1H) -ONA.
Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.